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Background
Immune thrombocytopenia purpura (ITP) can co-exist
with primary immunodeficiencies. Intravenous immuno-
globulin (IGIV) therapy is an effective treatment. Subcuta-
neous immunoglobulin (SCIG) formulations that can be
home-delivered have recently been developed. We describe
2 cases of pediatric ITP associated with hypogammaglobu-
linemia, treated with SCIG.
Case description
Case 1
A 14-year old male presented with a symptomatic
thrombopenia. Infusions of IGIV led to an immediate
improvement in platelet count. However, he experienced
post-infusion intractable headaches, nausea and vomiting,
which recurred after subsequent infusions. Intravenous
anti-D therapy resulted in a severe allergic reaction. Short
course prednisone protocol was implemented for sympto-
matic episodes. Preliminary blood work for splenectomy
revealed low IgG level. The patient was put on SCIG
replacement therapy (116 mg/kg/week). He experienced
only one relapse since, which remained corticoresponsive.
Case 2
A 14-year-old male was referred for asymptomatic
thrombo-neutropenia. Extensive work-up was normal. He
was administered IVIG after which the platelet count
quickly normalized. Eighteen months later, he developed
monoarthritis and generalized adenopathies. Dominant
lymph node biopsy showed reactive lymphoid hyperplasia.
The patient started to experience recurrent thrombopenia
flare-ups, needing monthly IVIG. Laboratory results indi-
cated low IgM and IgG levels. To prevent further episodes,
he received prophylactic monthly IVIG for 6 months
before switching to SCIG (135 mg/kg/week). Platelet and
also neutrophil levels normalized, which was not achieved
with IGIV.
In both patients, SCIG therapy was well-tolerated with
no adverse events occurring.
Conclusion
These results suggest that SCIG can be an effective and
convenient treatment of pediatric ITP.
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